Thermo Fisher Scientific Inc. announced the Sorvall RC 12BP Plus Centrifuge, a large-capacity, high-throughput floor standing centrifuge for blood banking and bioprocessing applications.
Chemical Abstracts Service, an authority on chemical information, announced that WuXi AppTec, the leading China-based contract research organization, has signed a contract to provide SciFinder for all scientists within their organization.
Reinnervate announced its expansion into a purpose-built research and production facility at NETPark near Sedgefield, UK. The move to the 10,000 square foot facility has enabled reinnervate to begin commercial production of its alvetex 3D cell culture.
Stage 1 of HealthLinx Limited’s multi-centre, multi-site second study for OvPlex has returned excellent initial data for the two new biomarkers AGR2 and HTX010 being evaluated for accuracy in diagnosing ovarian cancer.
Neovacs, a biotech company focused on the Kinoids technology platform for treatment of autoimmune diseases, inflammatory diseases and cancer has received DSMB authorization to proceed to a higher dosage in its ongoing phase 1/2 trial in lupus.
New University of Georgia research has found that blocking the action of an enzyme called GnT-V significantly delays the onset and spread of tumors in mice with cancer very similar to many cases of human breast cancer.
Discovery of a fifth gene defect and the identification of 47 DNA regions linked to thoracic aortic disease are the subject of studies released this month involving researchers at The University of Texas Health Science Center at Houston.
Many studies support the assertion that moderate drinking is beneficial when it comes to cardiovascular health, and for the first time scientists have discovered that a well-known molecule, called Notch, may be behind alcohol's protective effects.
New research may lead to exciting new approaches to targeting diseases such as cancer and there is potential for more targeted treatments following identification of proteins that play a vital role in the life of a human cell.
Successfully treating and reversing the effects of multiple sclerosis, or MS, may one day be possible using a drug originally developed to treat chronic pain. A single injection ATL313 stopped the progression of MS-caused paralysis in rats for weeks at a time.
Researchers have been stymied for years over the fact that people infected with the AIDS virus do indeed produce antibodies in response to the pathogen – antibodies that turn out to be ineffective in blocking infection.
Biotech drugmaker Amgen says federal health regulators approved its bone-strengthening drug for preventing fractures and skeletal-problems in patients with advanced cancer.
Full-body scanners pack a radiation dose that can peer through clothing for bombs or weapons, yet isn't harmful, federal officials insist. As holiday travelers flock to airports, the government is working to reassure the public that the machines are safe.
Pfizer Inc. said it is halting a late-stage study of its highly anticipated blood thinner apixaban, due to dangerous bleeding among patients with a history of heart disease. The drug, co-developed with Bristol-Myers Squibb Corp., has blockbuster potential.